A newly released observational analysis found that 84.4% of cancer patients treated off-label with a compounded combination of Ivermectin and Mebendazole experienced a clinical benefit.
Continue reading...
[ H/T Breitbart News ]
Headlines
Ivermectin + Mebendazole: Groundbreaking Study Reports 84.4% Clinical Benefit Rate in Cancer Patients
- Author Conservative Angle
- Published Published
- 1 min read
A newly released observational analysis found that 84.4% of cancer patients treated off-label with a compounded combination of Ivermectin and Mebendazole experienced a clinical benefit.
Continue reading...
[ H/T Breitbart News ]
